Table 2.

Comparison of characteristics according to serologically positive and negative groups

	Positive group (n = 11)	Negative group (n = 97)	P value
Sex (male/female)	6/5	61/36	0.74
Age (months)	29 (21–70)	24 (13–49.5)	0.26
Duration of fever (days)	6 (6–9)	5 (5–7)	0.092
Frequency of administration of IVIG	1 (1–2)	1 (1–1)	0.32
Acute-phase coronary artery dilation; n (%)	2 (18.18 %)	4 (4.12 %)	0.11
CS; n (%)	2 (18.18 %)	1 (1.03 %)	0.027
Abdominal symptoms; n (%)	8 (72.73 %)	33 (34.02 %)	0.02
White blood cell count (/μ L)	12,900 (11,100–19,400)	13,000 (10,750–15,400)	0.48
Absolute neutrophil count (/μ L)	8117 (5741–24,654)	8032 (5696–10,240)	0.73
Serum albumin concentration (g/dL)	3.8 (3.4–4)	3.7 (3.4–4)	0.54
Serum total bilirubin concentration (mg/dL)	0.4 (0.3–0.7)	0.6 (0.4–0.8)	0.47
Serum aspartate aminotransferase (U/L)	37 (19–230)	32.5 (25–69.25)	0.8
Serum sodium (mmol/L)	134 (133–138)	136 (134–138)	0.24
Serum CRP concentration (mg/dL)	4.36 (1.81–8.09)	7.09 (3.09–11.72)	0.27
Serum procalcitonin concentration (ng/mL)	0.67 (0.42–2.18)	0.47 (0.175–1.995)	0.37
N-terminal pro-brain natriuretic peptide (pg/mL)	379 (81.75–771.5)	386 (140–936)	0.74
Serum soluble interleukin-2 receptor (U/mL)	1560 (1350–2680)	1635 (1062.5–2157.5)	0.37
Urinary β 2-microglobulin/creatinine ratio	101.9 (10.7–203.7)	18.9 (5.9–126.3)	0.25
High risk patients; n (%)	3 (27.27 %)	26 (27.08 %)	1

Values expressed as count (%) for categorical variables and median (IQR) for continuous variables